We are pleased to share that our new publication, developed in partnership with the IFPA International Federation of Psoriasis Associations, ” Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction”, […]
We’re excited to share our latest manuscript “Real-world Utilization of Biologic and targeted Synthetic Disease- Modifying Anti- Rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis : Insights from Sweden and Germany”” now […]
We are delighted to share that the NORDSTAR manuscript “Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma- findings from the NORDSTAR cohort” is now available online, co-authored by Quantify’s Patrik Sandin, Alexandra Cooper, Olivia […]
Quantify’s recent report, “A Review of Progress Since the WHA Resolution on Psoriasis,” was highlighted at this year’s World Psoriasis Day event in Geneva, with representatives from World Health Organization Member States’ Permanent Missions […]
Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion […]
In December 2023, Quantify’s Stuti Arya, Nicholas Norton and Puneet Kaushik published a study assessing recent changes to adult national immunization programs for pneumococcal vaccination and attempting to determine how those changes impacted coverage in European Adults. The review revealed […]
In April 2024, Quantify’s Helena Skröder and Nicholas Norton published a study quantifying the burden of acute otitis media (AOM) caused by pneumoniae, after widespread use of PCVs. The review found […]
Quantify Research is recognized as one of the 10 most cited publications last year in the renowned journal Alzheimer’s & Dementia!
Our work with Project Alzheimer Value Europe titled “Global estimates on the number of […]
Make sure you’ve read Quantify’s CEO Kirk Geale‘s PharmaTimes article published late last year, explaining how global pharmaceutical executives can harness the power of Scandinavian health data to achieve regulatory and commercial success.